Stock Research for AFFY

Current Price


Latest Update: 2018-02-16 12:07:00

$ 0.0258
$ 0.0258
$ 0.0258

Featured Broker: TradeStation

Get the due diligence for another stock.


AFFY Stock Chart & Research Data

The AFFY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AFFY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


AFFY Due diligence Resources & Stock Charts

The AFFY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AFFY Detailed Price Forecast - CNN Money CNN View AFFY Detailed Summary - Google Finance
Yahoo View AFFY Detailed Summary - Yahoo! Finance Zacks View AFFY Stock Research & Analysis -

Stock Analysis

TradeIdeas View AFFY Trends & Analysis - Trade-Ideas Barrons View AFFY Major Holders - Barrons
NASDAQ View AFFY Call Transcripts - NASDAQ Seeking View AFFY Breaking News & Analysis - Seeking Alpha
Spotlight View AFFY Annual Report - OTC Report View AFFY OTC Short Report -
TradeKing View AFFY Fundamentals - TradeKing Charts View AFFY SEC Filings - Bar Chart
WSJ View Historical Prices for AFFY - The WSJ Morningstar View Performance/Total Return for AFFY - Morningstar
MarketWatch View the Analyst Estimates for AFFY - MarketWatch CNBC View the Earnings History for AFFY - CNBC
StockMarketWatch View the AFFY Earnings - StockMarketWatch MacroAxis View AFFY Buy or Sell Recommendations - MacroAxis
Bullish View the AFFY Bullish Patterns - American Bulls Short Pains View AFFY Short Pain Metrics -

Social Media Mentions

StockTwits View AFFY Stock Mentions - StockTwits PennyStocks View AFFY Stock Mentions - PennyStockTweets
Twitter View AFFY Stock Mentions - Twitter Invest Hub View AFFY Investment Forum News - Investor Hub
Yahoo View AFFY Stock Mentions - Yahoo! Message Board Seeking Alpha View AFFY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for AFFY - Insider Cow View Insider Transactions for AFFY - Insider Cow
CNBC View AFFY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AFFY - OTC Markets
Yahoo View Insider Transactions for AFFY - Yahoo! Finance NASDAQ View Institutional Holdings for AFFY - NASDAQ

Stock Charts

FinViz View AFFY Stock Insight & Charts - StockCharts View AFFY Investment Charts -
BarChart View AFFY Stock Overview & Charts - BarChart Trading View View AFFY User Generated Charts - Trading View

Latest Financial News for AFFY

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen
Seeking Alpha - Aug 28, 2013
After Affymax and Takeda (collaboration partner) commercialized Omontys in the U.S. in 3Q 2012, the drug was "voluntarily" recalled in February of this year due to serious hypersensitivity reactions, including anaphylaxis resulting in death in certain ...

Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.

Don't Believe In Affymax - The Stock Is Probably Worthless
Seeking Alpha - Aug 29, 2013
Investors in Affymax (NASDAQ:AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the ...

Affymax stock plunges 85 percent on drug recall
Reuters - Feb 25, 2013
(Reuters) - Shares of Affymax Inc AFFY.O fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS - Business Wire (press release)
Affymax Is Done. RIP. -

Enter a stock symbol to view the stock details.